This also allows for the development of novel therapeutic targets that act like sRAGE and sTM, in a manner less burdensome and potentially with fewer side effects than by administering neutralizing antibodies to HMGB1, such as recently used by others in rat models of stroke, TBI, and Parkinson’s disease [49, 50, 69]. Here, HMGB1 is linked to Parkinson disease.